{{Rsnum
|rsid=6779828
|Gene=GSK3B
|Chromosome=3
|position=120056300
|Orientation=plus
|GMAF=0.2452
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GSK3B
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 55.4 | 36.9 | 7.7
| HCB | 88.6 | 11.4 | 0.0
| JPT | 93.2 | 6.8 | 0.0
| YRI | 23.3 | 40.0 | 36.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 88.6 | 11.4 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|18500637}} [[rs7624540]], [[rs4072520]], [[rs6779828]] showed genotypic association with [[schizophrenia]]
{{PMID Auto
|PMID=20605420
|Title=Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
}}

{{PMID Auto
|PMID=18676680
|Title=Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}